What is HC Wainwright’s Forecast for PHIO Q2 Earnings?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Phio Pharmaceuticals in a research note issued on Thursday, June 5th. HC Wainwright analyst M. Keller anticipates that the company will earn ($0.36) per share for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($0.41) EPS.

Phio Pharmaceuticals Price Performance

Shares of NASDAQ:PHIO opened at $2.96 on Friday. The firm has a market capitalization of $14.20 million, a PE ratio of -0.27 and a beta of 0.99. The business has a 50-day moving average of $1.92 and a two-hundred day moving average of $2.01. Phio Pharmaceuticals has a 12 month low of $0.97 and a 12 month high of $9.79.

Institutional Investors Weigh In On Phio Pharmaceuticals

A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned about 0.59% of Phio Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.